688098 Shanghai Shen Lian Biomedical Corporation
- 5.05
- +0.06+1.20%
Shanghai Shen Lian Biomedical Corporation News
Special explanation on the use of capital by the controlling shareholder and other related parties of Shenlian Biopharmaceuticals (Shanghai) Co., Ltd.
2023 Independent Director Debriefing Report of Shenlian Biopharmaceuticals (Shanghai) Co., Ltd. (Wu Shouchang)
2023 Independent Director Debriefing Report of Shenlian Biopharmaceuticals (Shanghai) Co., Ltd. (Li Jianjun)
Announcement on the 2023 Profit Distribution Plan
Notice on revising the “Articles of Association” and some regulatory operating systems
Constitution of Shenlian Biopharmaceuticals (Shanghai) Co., Ltd.
Rules of procedure for the shareholders' meeting of Shenlian Biopharmaceuticals (Shanghai) Co., Ltd.
Rules of procedure for the board of directors of Shenlian Biopharmaceuticals (Shanghai) Co., Ltd.
Independent director system for Shenlian Biopharmaceuticals (Shanghai) Co., Ltd.
Working rules for the special meeting of independent directors of Shenlian Biopharmaceuticals (Shanghai) Co., Ltd.
Shenlian Biopharmaceutical (Shanghai) Co., Ltd. related transaction management system
Shenlian Biopharmaceuticals (Shanghai) Co., Ltd. Fund Raising Management System
2024 First Quarter Report
Announcement of Resolutions of the 12th Meeting of the Third Board of Directors
Announcement of Resolutions of the 9th Meeting of the Third Board of Supervisors
Special report on the storage and use of funds raised in 2023
Guoxin Securities Co., Ltd. inspection opinions on the storage and actual use of funds raised by Shenlian Biopharmaceuticals (Shanghai) Co., Ltd. in 2023
Dahua Certified Public Accountants (Special General Partnership) Verification Report on the Deposit and Use of Funds Raised by Shenlian Biopharmaceuticals (Shanghai) Co., Ltd.
Announcement on the adjustment of the audit committee members of the third board of directors of the company
Announcement on the retirement and resignation of the company's financial director and the appointment of the financial director
Analysis
Price Target
No Data
